TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02953184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: 35mg/m2 iv drop during the first 4 cycles every three week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 IV drop during the first 4 cycles every three week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600mg/m2 IV drop during the first 4 cycles every three week
Study: NCT02527148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OtisMed® ShapeMatch® Technology
Description: The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Precision Knee Navigation
Description: Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon® Total Knee System
Description: Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon® Total Knee System
Description: Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon.
Study: NCT02953184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 100mg/m2 IV drop during the last 4 cycles every three week
Study: NCT02466165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Study: NCT02953184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: 100mg/m2 IV drop during the last 4 cycles every three week
Study: NCT03633565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil (Phosphodiesterase inhibitors)
Description: tablet 25mg
Study: NCT02758990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Subjects will be asked to increase Nicotinamide intake by 500 mg per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Subjects will be asked to increase vitamin E intake by 400 International Units per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
Study: NCT03633565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone (Steroids)
Description: tablet 20 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation
Description: stem cell transplantation intramuscular
Study: NCT03541655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Description: 0.25% Bupivacaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 0.25% Bupivacaine HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F14 (celecoxib)
Description: Celecoxib in novel drug delivery system (BEPO™)
Study: NCT02758990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach
Description: Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach
Description: Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
Study: NCT02953184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexrazoxane (DZR)
Description: DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
Study: NCT01120379

Intervention type: DEVICE
Intervention: XIENCE V® EECSS
Description: Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
Study: NCT00546793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
Study: NCT03445754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TVS
Description: Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
Study: NCT00881361

Intervention type: DRUG
Group type: OTHER
Intervention: systemic chemotherapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: axillary lymph node dissection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study: NCT02953184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B
Description: Vitamin B will be administrated for protecting HFS in PLD group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Conserved Surgery
Description: Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Conserved Surgery
Description: Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Radical Mastectomy
Description: Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Radical Mastectomy
Description: Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy（SLNB）
Description: Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy（SLNB）
Description: Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
Study: NCT04275076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia
Description: comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia
Description: comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
Study: NCT00051714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Preventive Intervention
Study: NCT03534882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of topical prostaglandin analogue therapy
Description: Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
Study: NCT00881361

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound imaging
Study: NCT01008618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
Study: NCT00888147

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fiber containing tube feeding formula
Description: This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
Study: NCT03534050

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative adjuvant RT
Study: NCT02758990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
Study: NCT04429464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQBlate Force Sensing Ablation Catheter
Description: Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
Study: NCT04142216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
Study: NCT04435314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Subjects will receive nitazonanide 600 mg TID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo TID for 7 days.
Study: NCT02268643

Intervention type: OTHER
Intervention: ultrasound plus clinical breast examination
Description: all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
Study: NCT02758990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
Study: NCT06263036

Intervention type: OTHER
Intervention: Men
Description: Laryngeal cartilages

Intervention type: OTHER
Intervention: Men
Description: Laryngeal cartilages

Intervention type: OTHER
Intervention: Women
Description: Laryngeal cartilages

Intervention type: OTHER
Intervention: Women
Description: Laryngeal cartilages
Study: NCT02785328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory evaluation at V1 and V2 (with treatment)
Description: Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory evaluation at V1 and V2 (with treatment)
Description: Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
Study: NCT00983359

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
Study: NCT02637024

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI: 30 Gy
Description: 30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI: 27.5 Gy
Description: 27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
Study: NCT01841918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avian Flu Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Avian Flu Vaccine
Study: NCT01113554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study: NCT03111017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
Study: NCT01240408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOPE
Description: 10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
Study: NCT03690596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NRT + QuitBuddy
Description: QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
Study: NCT01240408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOPE
Description: 10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
Study: NCT03690596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NRT + QuitBuddy-Recall
Description: QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: 1 month supply of 4 mg nicotine lozenge
Study: NCT02980874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suprachoroidal sham
Description: suprachoroidal sham procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVT aflibercept
Description: 2 mg intravitreal injection of aflibercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVT aflibercept
Description: 2 mg intravitreal injection of aflibercept
Study: NCT02785328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory evaluation at V1 and V2 (with treatment)
Description: Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
Study: NCT00793182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ioversol 320 mgI/mL
Description: 125 mL of Ioversol administered in the vein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol 320 mgI/mL
Description: 125 mL of Iodixanol administered in the vein
Study: NCT03930420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect to Wellness
Description: The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connect to Wellness
Description: The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
Study: NCT01226212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic (Synergy 1/B. longum)
Description: Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrose
Study: NCT02785328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory evaluation at V1 (without treatment)
Description: Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory evaluation at V1 and V2 (without treatment)
Description: Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
Study: NCT01507701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
Study: NCT01861847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7-Keto Dehydroepiandrosterone
Description: 7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Study: NCT05361265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fetal movement counting
Description: pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
Study: NCT02307838

Intervention type: OTHER
Group type: OTHER
Intervention: Assessments arm
Description: Protocol required assessments not provided in standard of care
Study: NCT04008108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity sensor
Description: Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
Study: NCT02679443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate and B12
Description: Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
Study: NCT00879463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain tissue oxygen saturation monitoring
Description: Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy